36P PROUDER-BC: PROsigna in UnDer-50-year-old patients (pts) with endocrine receptor-positive (ER+) breast cancer (BC) for chemotherapy (CT) prescriptionFrancesco Schettini, T. Pascual, G Grazia et al.|ESMO Open|2025Cited by 0
347P Chemotherapy (CT) and GnRH analogue (a) benefit in patients (pts)≤50 years (y) with estrogen receptor-positive (ER+)/HER2-negative (-) stage I–II breast cancer (BC) risk-stratified by ProsignaF. Schettini, Vincenzo Di Lauro, D. Morchón Araujo et al.|Annals of Oncology|2025Cited by 0